Autopsy report · NCT01211691

Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)

“KaloBios to Wind Down Operations”

The sponsor’s own words in the registry.

Life of this trial

• Suspended: paused, and may or may not restart.
• 120 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 1, Phase 2

Sponsor

Humanigen, Inc.

Sponsor type

Industry

Conditions

Myelodysplastic Syndrome (MDS); Myelofibrosis (MF)

Interventions

KB004, Monoclonal Antibody

Participants

120 (planned, not actual)

Sites

9

Countries

Australia, United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.